Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.

Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A, ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC

Open source

DOI: 10.1016/s2666-7568(23)00284-2
Published: 2024 Mar
Container: The lancet. Healthy longevity
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2666-7568-23-00284-2,
  title = {Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.},
  author = {Guigay J and Ortholan C and Vansteene D and Cupissol D and Even C and Kaminsky MC and Sire C and Blot E and Debourdeau P and Bozec L and Saada-Bouzid E and Fayette J and Dalloz P and Pointreau Y and Caer HL and Falandry C and Digue L and Braccini A and Lopez S and Guillet P and Michel C and Cheurfa N and Schwob D and Bourhis J and Mertens C and Aupérin A and ELAN Group including Gustave Roussy, Unicancer GERICO and H\&N groups and the GORTEC},
  year = {2024},
  journal = {The lancet. Healthy longevity},
  doi = {10.1016/s2666-7568(23)00284-2},
  url = {https://doi.org/10.1016/s2666-7568(23)00284-2}
}

RIS

TY  - JOUR
TI  - Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
AU  - Guigay J
AU  - Ortholan C
AU  - Vansteene D
AU  - Cupissol D
AU  - Even C
AU  - Kaminsky MC
AU  - Sire C
AU  - Blot E
AU  - Debourdeau P
AU  - Bozec L
AU  - Saada-Bouzid E
AU  - Fayette J
AU  - Dalloz P
AU  - Pointreau Y
AU  - Caer HL
AU  - Falandry C
AU  - Digue L
AU  - Braccini A
AU  - Lopez S
AU  - Guillet P
AU  - Michel C
AU  - Cheurfa N
AU  - Schwob D
AU  - Bourhis J
AU  - Mertens C
AU  - Aupérin A
AU  - ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC
PY  - 2024
JO  - The lancet. Healthy longevity
DO  - 10.1016/s2666-7568(23)00284-2
UR  - https://doi.org/10.1016/s2666-7568(23)00284-2
ER  -

APA

J, G., C, O., D, V., D, C., C, E., MC, K., C, S., E, B., P, D., L, B., E, S., J, F., P, D., Y, P., HL, C., C, F., L, D., A, B., S, L., P, G., C, M., N, C., D, S., J, B., C, M., A, A., & GORTEC, E. G. I. G. R. U. G. A. H. G. A. T. (2024). Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.. The lancet. Healthy longevity. https://doi.org/10.1016/s2666-7568(23)00284-2

Source records

pubmed · retrieved 2026-09-25T22:27:36.181Z